Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Brickell Biotech Inc (BBI)

Brickell Biotech Inc (BBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Brickell Biotech Inc 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301 USA

www.brickellbio.com P: 720-505-4755

Description:

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company. It is focused on developing prescription therapeutics for treatment of skin diseases. The company's pipeline consists of therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. Its products include Prozac(R), Gemzar(R), Cialis(R), Evista(R), Talz(R), Humulin(R), Cymbalta(R), Dysport(R), Juvederm(R) and Kybella(R). Brickell Biotech Inc., formerly known as Vical Incorporated, is based in San Diego, United States.

Key Statistics

Overview:

Market Capitalization, $K 6,754
Enterprise Value, $K -20,126
Shares Outstanding, K 2,874
Annual Sales, $ 400 K
Annual Net Income, $ -39,470 K
Last Quarter Sales, $ 4,320 K
Last Quarter Net Income, $ -1,150 K
60-Month Beta 0.02
% of Insider Shareholders 4.53%
Float, K 2,744
% Float 95.47%
Short Volume Ratio 0.34

Growth:

1-Year Return -93.63%
3-Year Return -98.84%
5-Year Return -99.69%
5-Year Revenue Growth -97.25%
5-Year Earnings Growth 92.22%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 08/11/22
Latest Earnings Date N/A
Earnings Per Share ttm -13.52
EPS Growth vs. Prev Qtr 99.72%
EPS Growth vs. Prev Year 99.86%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payable Date 06/02/05
Dividend Payout Ratio 0.00%
Most Recent Split 1-45 on 07/05/22

BBI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -156.10%
Return-on-Assets % -128.23%
Profit Margin % -9,867.50%
Debt/Equity 0.00
Price/Sales 16.36
Price/Cash Flow N/A
Price/Book 0.40
Book Value/Share 5.90
Interest Coverage -562.86
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar